Comments on the results of the ADOPT study
https://doi.org/10.14341/probl20085437-11
Abstract
Type 2 diabetes mellitus (T2DM) - the "non-infectious epidemic" of our time - now occupies one of the leading positions in the world in terms of the severity of the disease (death + disability). Mortality of patients with T2DM is 2.3 times higher than mortality among the general population. Every year, diabetes is the cause of death of approximately 3.8 million people.
References
1. Карпов О. И. // Рус. мед. журн. - 2006. - № 26. - Р. 3-6.
2. Al-Ozpiri Е., Sibal L., Лоте Р. // Diabetes Саге. - 2007. - Vol. 30. - Р. 1677-1680.
3. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997 // Diabetes Care. - 199S. - Vol. 21. - P. 296-309.
4. Bloomgarden Z. T. // Diabetes Care. - 2007. - Vol. 30. - P. 2401-2403.
5. The CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes // J. A. M. A. - 2002. - Vol. 287. - P. 2542-2551
6. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes // N. Engl. J. Med. - 2005. - Vol. 353. - P. 2643-2653.
7. Global Prevalence of Diabetes Set to Top 380 Million by 2025 News, Reuters Health Information, December 2006.
8. Grey A., Bolland M. Gamble G. et al. // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92, N 4. - P. 1305-1310.
9. Kahn S. E., Haffner S. M., Ifeise M. A. et al. // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2427-2443.
10. Kannel W. В., McCee D. L. // Circulation. - 1979. - Vol. 59. -P. 8-13.
11. Lipscombe L. L., Comes Т., Levesque L. E. et al. // J. A. M. A. - 2007. - Vol. 293. - P. 2634-2643.
12. Muhammad S. // Compcnd. Contin. Educ. Dent. - 2004. - Vol. 25, N 3. - P. 195-193; 200; 202.
13. Murray С. J., Lopez A. D. The Global Burden of Disease. - Geneva, 1996.
14. Nissen S. E., H'olski К. // N. Engl. J. Med. - 2007. -Vol. 356, N 24. - P. 2457-2471.
15. Singh A., Blackwell J., Neher J. // J. Fam. Pract. - 2005. -Vol. 54, N 4. - P. 370-372.
16. UKPDS Group: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41): United Kingdom Prospective Diabetes Study Group // Br. Med. J. - 2000. - Vol. 320. - P. 1373-1378.
17. United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1993. - Vol. 352. - P. 837-853.
18. Viberti C., Kahn S. Е., Greene D. A. et al. // Diabetes Care. - 2002. - Vol. 25. - P. 1737-1743.
19. Yaturu S., Bryant В., Jain S. K. // Diabetes Care. - 2007. - Vol. 30.-P. 1574-1576.
Review
For citations:
Ushkalova Ye.A. Comments on the results of the ADOPT study. Problems of Endocrinology. 2008;54(3):7-11. (In Russ.) https://doi.org/10.14341/probl20085437-11
Views:
573
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
